WO2019219713A1 - Microparticules de protéines gélifiées riches en cannabinoïdes - Google Patents

Microparticules de protéines gélifiées riches en cannabinoïdes Download PDF

Info

Publication number
WO2019219713A1
WO2019219713A1 PCT/EP2019/062395 EP2019062395W WO2019219713A1 WO 2019219713 A1 WO2019219713 A1 WO 2019219713A1 EP 2019062395 W EP2019062395 W EP 2019062395W WO 2019219713 A1 WO2019219713 A1 WO 2019219713A1
Authority
WO
WIPO (PCT)
Prior art keywords
gelated
cannabinoid
microparticle
protein
rich
Prior art date
Application number
PCT/EP2019/062395
Other languages
English (en)
Other versions
WO2019219713A9 (fr
Inventor
Donny Christian MISTARZ
Henrik KRISTIANSEN
Sinead BLEIEL
Original Assignee
Plantine Production Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plantine Production Uk Limited filed Critical Plantine Production Uk Limited
Priority to EP19728883.0A priority Critical patent/EP3793528A1/fr
Publication of WO2019219713A1 publication Critical patent/WO2019219713A1/fr
Publication of WO2019219713A9 publication Critical patent/WO2019219713A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to cannabinoid-rich gelated protein microparticles containing hemp oil, and compositions comprising the microparticles. Also contemplated are uses of the microparticles.
  • Hemp oil is recognised for its medicinal and nutritional qualities, partly due to the high amounts of cannabinoids, including cannabidiol (CBD), which have been indicated for numerous conditions including pain associated with multiple sclerosis, inflammatory conditions, and epilepsy.
  • CBD cannabidiol
  • cannabinoids for mammals is hindered by Hemp Oil’s low oral bioavailability. This means that, when given orally, very little CBD reaches the bloodstream. The reason for this is that Hemp Oil and CBD are highly susceptible to oxidation and enzymatic degradation in the gastrointestinal tract and has very low permeability across the gut wall.
  • a further problem associated with hemp oil products is the small and taste of the oil, and the difficulty providing hemp oil in a form in which it can be easily incorporated into aqueous products.
  • MELISSA TIESSEN-DYCK sums up a variety of prior art and published papers relating to pea protein.
  • the paper is a Thesis submitted to the Faculty of graduate Studies of The University of Manitoba In Partial Fulfilment of the Requirements of the Degree of MASTER OF SCIENCE, Department of Food Science, University of Manitoba, Winnipeg.
  • W002/064109 describes process for extraction of pharmaceutically active cannabinoids from plant material followed by cold filtration, decarboxylation and purification.
  • W002/092217 described microcapsules containing a mixture of at least one solubilised vegetable protein and a polyelectrolyte with an opposite charge to the protein, that are subjected to coacervation in an aqueous medium.
  • WO2012/038061 describes polymeric nanocapsules containing microemulsions of water in oil and at least one hydrophilic active ingredient dissolved in the aqueous phase.
  • EP0856355 describes enzymatic crosslinking of protein-encapsulated oil particles by complex coacervation.
  • US5271961 describes protein microspheres formed by phase separation in a non-solvent followed by solvent removal.
  • the present invention addresses the need for a hemp-based product, including versions which contains high-amounts of cannabinoids, is water dispersible, is taste and small masked, and that provides cannabinoids in highly bioavailable form.
  • These objectives are met by providing phyto-cannabinoid rich hemp oil in a microparticulate form comprising gelated microparticles having a continuous protein matrix and micro-emulsified hemp oil dispersed throughout the matrix.
  • the gelated microparticles are generally created by forming an aqueous micro-emulsion comprising hemp oil, surfactant and protein by high- shear homogenisation, and extruding the micro-emulsion into microdroplets which are cured in a polymerisation bath.
  • microparticles contain high amounts of cannabinoid (for example more than 40 mg cannabinoid per gram of microparticles), are water-dispersible, and are capable of passing through the human stomach intact (gastro- resistant) and breaking down and releasing the cannabinoid-rich hemp oil in the ileum (ileal-sensitive).
  • cannabinoid for example more than 40 mg cannabinoid per gram of microparticles
  • microparticles provide hemp oil in a stabilised form that is resistant to oxidation for up to 18 months,
  • a gelated microparticle comprising micro-emulsified hemp oil dispersed throughout a polymerised protein matrix, in which the microparticle is typically gastro-resistant, ileal-sensitive and bioavailable in a mammal.
  • a gelated microparticle comprising hemp powder dispersed throughout a polymerised protein matrix, in which the microparticle is typically gastro-resistant, ileal-sensitive and bioavailable in a mammal.
  • the hemp powder may be any part of the hemp plant.
  • the hemp powder is micronized hemp plant material.
  • the micro-emulsified hemp oil is stable to oxidation.
  • the microparticle is cannabinoid-rich.
  • the micronized hemp oil comprises a surfactant.
  • the surfactant comprises a polysorbate-type non-ionic surfactant.
  • the polysorbate-type non-ionic surfactant is TWEEN (RTM)-20.
  • the protein is selected from dairy protein and / or vegetable protein.
  • the protein is selected from milk protein isolate and / or pea protein.
  • the gelated microparticle comprises 10 to 50 % protein, 2 to 6 % surfactant, and 40 to 90% hemp oil (w/w).
  • the gelated microparticle comprises 20 to 40 % protein, 2 to 6 % surfactant, and 50 to 90% hemp oil (w/w).
  • the gelated microparticle comprises 35 to 40 % protein, 2 to 6 % surfactant, and 55 to 65 % hemp oil (w /w).
  • the gelated microparticle comprises the microparticle is dried. In one embodiment, the gelated microparticle is dried to a water activity (Aw) of less than 0.40, 0.30 or preferably less than 0.20.
  • the gelated microparticles may be dried by, for example, spray drying.
  • the gelated microparticle comprises more than 8% cannabidiol (CBD) (w/w). In one embodiment, the gelated microparticle comprises more than 12% cannabidiol (CBD) (w/w). In one embodiment, the gelated microparticle comprises more than 15% cannabidiol (CBD) (w/w). In one embodiment, the gelated microparticle comprises more than 20% cannabidiol (CBD) (w/w). In one embodiment, the gelated microparticle comprises more than 30% cannabidiol (CBD) (w/w). In one embodiment, the gelated microparticle comprises more than 40% cannabidiol (CBD) (w/w). In one embodiment, the gelated microparticle comprises more than 50% cannabidiol (CBD) (w/w).
  • CBD cannabidiol
  • the hemp oil comprises less than 0.20% tetrahydrocannabinol (THC) (w/w).
  • the gelated microparticle comprises less than 0.10%
  • THC tetrahydrocannabinol
  • the hemp oil is provided in the form of hemp plant material (i.e. hemp seeds or plant matter).
  • the hemp plant material is powdered hemp plant material.
  • hemp powder should be understood to mean any part of the hemp plant, typically the above-the-ground parts, in a powdered form.
  • a powder composition comprising a multiplicity of dried gelated microparticles according to the invention.
  • composition suitable for oral administration to a human comprising a multiplicity of microencapsulates according to the invention.
  • the composition is selected from a food product, a beverage, a food ingredient, a nutritional supplement, an infant formula or oral dosage pharmaceutical.
  • the gelated microparticles have an average dimension of about 10 to about 250 microns, about 50 to about 200 microns, about 50 to about 150 microns, about 90 to about 200 microns, about 80 to about 120 microns.
  • the invention also provides a gelated micropartice of the invention, or a composition of the invention, for use in a method selected from:
  • the method comprises the steps of:
  • the hemp oil is provided in the form of hemp powder, typically micronized hemp powder.
  • the hemp powder is mixed with a protein solution/suspension in the absence of added surfactant.
  • the homogenisation step employs a high shear rotor-stator homogeniser.
  • a high shear rotor-stator homogeniser examples include UltraTurrax (RTM) homogenisers.
  • the homogenisation step comprises mixing surfactant and protein under high shear conditions to produce a pre-mixture in which the surfactant is dissolved, and then addition of the oil to the pre-mixture under high shear conditions.
  • the polymerisation bath is an acidification bath.
  • the acidification bath comprises an acetate buffer.
  • the polymerisation bath is agitated to create a vortex during the curing step.
  • the surfactant comprises a non-ionic surfactant, typically a
  • the polysorbate-type non-ionic surfactant is TWEEN (RTM)-20.
  • the protein is selected from milk protein or vegetable protein.
  • the aqueous microemulsion is de-gassed prior to the extrusion step.
  • the gelated microparticles are dried by spray-drying.
  • a hygroscopicity aid is added to the gelated microparticles at the drying stage.
  • the hygroscopicity aid minimises moisture adsorption, provides excellent dispersibility, and enhances rheological behaviour to enable the final powder to be used in various product applications.
  • the dried microparticles are sieved after drying.
  • the present invention provides a hemp derivative rich, -or cannabinoid rich powder that is water-dispersible, taste-masked; stomach resistant, ileal released, and highly bioavailable. It has reduced aroma and taste of the encapsulated material relative to un-encapsulated form. It has significantly improved bio-availability profile compared to the same in its un-encapsulated form. It is a dry stable powder with versatility for human supplement and food applications, free from primary and secondary oxidation, and a product that is protected from environmental conditions for manufacture and has an increased shelf life compared to non-encapsulated forms.
  • the active ingredients are all derived from or extracted, from European industrial hemp varieties, using any known conventional industrial extraction method, such as SC-CC>2 or ethanol extraction.
  • the level of processing behind the product to be encapsulated can be fully tailored to suit the need of the client and the end use. It provides a simple and natural hemp derivative or hemp oil vehicle, that is fully plant-based using two macro-components and relevant processing aids. It has a significantly higher bio-availability degree, compared to regular cannabinoid rich extracts and hempseed oil-based extracts.
  • the surfactant comprises of a concentration between 1-20% from one or more of the following: a. Lecithin b. Vegetable Glycerin
  • the core material instead of hemp oil, comprises of micro emulsified powdered hemp, made from any of the, above the ground, parts of the hemp plant, dispersed throughout a polymerized protein matrix, in which the microparticle is gastro-resistant and small intestine-sensitive in which the microemulsified hemp powder is stable to oxidation.
  • the composition of the invention comprises a cannabinoid-rich gelated microparticle according to the invention, which is carrying any quantifiable level of a food or feed ingredient, a nutritional supplement, a functional food an active pharmaceutical ingredient (API) or a human or animal drug,
  • a cannabinoid-rich gelated microparticle according to the invention which is carrying any quantifiable level of a food or feed ingredient, a nutritional supplement, a functional food an active pharmaceutical ingredient (API) or a human or animal drug
  • Figure 1 A Hemp oil (88%) dark green to brown colour oil with slight odour and dry resultant microparticulated generated using a highly concentrated oil material.
  • FIG 3 (L-R): Micro-emulsion comprising hemp oil, surfactant and protein at low and high loading concentrations. No significant visible difference for reproducible processing.
  • Figure 4 (L-R) A, B: Hemp Oil micro-emulsion degassed prior to micro-encapsulation (A) and microscopic visualisation (B) of homogenous, stable micro-emulsion (magnification x200).
  • Figure 5 (L-R) A, B, C Dry gelated micro-particulates with different concentrations and particle sizes. Images illustrate the free-flowing nature of the material to enable a range of product applications.
  • FIG. 6 A, B; Microscopy image of dry gelated hemp oil micro-particulates at 40x (A) and 100x (B) magnification.
  • FIG. 1 Microscope image of hemp Oil micro-particulates after salivary digestion (microparticulate diameter approx. 180 urn) and no evidence of disturbance / digestion. Magnification x200.
  • Figure 8 (L-R): A, B, C. Microscope image of hemp Oil microparticulates after 1 hour (A), 2 hour (B) stomach incubation (37DegC; pH 1.8) and nno evidence of damage or release of oil. Images show the environmental digesta surrounding the microparticulates. Image C shows the free hemp oil after 2 stomach incubation. Magification x 40.
  • Figure 9 lmage_Hemp Oil Microparticulates after 2 hour gastric / stomach incubation. Microparticulates were not dissolved and remain intact during this step and demonstrate the robustbness of the Hemp Oil Microparticulates and resistance to stomach digestion.
  • FIG. 10 L-R: A, B: Free hemp oil remains floating on surface of gastric fluid (A) and flotation Activity (FA) is lost relatively fast during gastric incubation (B), which has a detrimental effect on Hemp oil functionality. It is clear that gastric protection is needed via microparticulates to maintain Hemp oil functionality.
  • Figure 11 Hemp Oil Microparticulates 15 minutes after intestinal incubation (15 minutes, 37 DegC pH 7.2). Magification x 40.
  • Figure 12 Hemp Oil Micro-particulates 30 minutes after intestinal Incubation (30 minutes, 37 DegC pH 7.2). Magification x 40.
  • Figure 13 Hemp Oil Microparticulates after 60 min Intestinal Incubation (60 minutes, 37 DegC pH 7.2). Magification x 40.
  • FIG. 14 Hemp Oil Microparticulates after 90 min intestinal digestion. Microparticulates are visibly digested and oil is liberated.
  • FIG. 15 (T - B) A, B): Hemp Oil CBD Content Calibration Histogram (A) and standard cureve (B) for quantification of dose response.
  • Figure 16 Quantification and Calibration of Hemp Oil CBD Content prior to In Vitro Digestion with relevant compensation for background / baseline values.
  • Figure 17 Quantification of Hemp Oil CBD Content after In Vitro Digestion demonstrating free CBD content after intestinal digestion. This demonstrates a highly efficient process.
  • Figure 19 Figure 19A, B and C show the emulsion preparation prior to micro- encapsulation.
  • Figure 20 shows the micro-encapsulation (under magnification) particles generated using the invention presented. Images endorse the robust process and illustrate the reproducible particle size achieved using the process.
  • “comprising,” are to be read to indicate the inclusion of any recited integer (e.g. a feature, element, characteristic, property, method/process step or limitation) or group of integers (e.g. features, element, characteristics, properties, method/process steps or limitations) but not the exclusion of any other integer or group of integers.
  • the term “comprising” is inclusive or open-ended and does not exclude additional, unrecited integers or method/process steps.
  • the term“disease” is used to define any abnormal condition that impairs physiological function and is associated with specific symptoms.
  • the term is used broadly to encompass any disorder, illness, abnormality, pathology, sickness, condition or syndrome in which physiological function is impaired irrespective of the nature of the aetiology (or indeed whether the aetiological basis for the disease is established). It therefore encompasses conditions arising from infection, trauma, injury, surgery, radiological ablation, poisoning or nutritional deficiencies.
  • treatment refers to an intervention (e.g. the administration of an agent to a human) which cures, ameliorates or lessens the symptoms of a disease or removes (or lessens the impact of) its cause(s) (for example, the reduction in accumulation of pathological levels of lysosomal enzymes).
  • intervention e.g. the administration of an agent to a human
  • cures ameliorates or lessens the symptoms of a disease or removes (or lessens the impact of) its cause(s) (for example, the reduction in accumulation of pathological levels of lysosomal enzymes).
  • the term is used synonymously with the term“therapy”.
  • treatment refers to an intervention (e.g. the administration of an agent to a human) which prevents or delays the onset or progression of a disease or reduces (or eradicates) its incidence within a treated population.
  • intervention e.g. the administration of an agent to a human
  • treatment is used synonymously with the term“prophylaxis”.
  • an effective amount or a therapeutically effective amount of an agent defines an amount that can be administered to a human without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio, but one that is sufficient to provide the desired effect, e.g. the treatment or prophylaxis manifested by a permanent or temporary improvement in the subject's condition.
  • the amount will vary from human to human, depending on the age and general condition of the individual, mode of administration and other factors. Thus, while it is not possible to specify an exact effective amount, those skilled in the art will be able to determine an appropriate "effective" amount in any individual case using routine experimentation and background general knowledge.
  • a therapeutic result in this context includes eradication or lessening of symptoms, reduced pain or discomfort, prolonged survival, improved mobility and other markers of clinical improvement. A therapeutic result need not be a complete cure.
  • Micro-encapsulate means a particle having an average dimension in the range of 20-250 microns, preferably 80-120 microns as determined using a method of laser diffractometery (Mastersizer (RTM) 2000, Stable Micro Systems, Surrey, UK). This method determines the diameter, mean size distribution and D (v, 0.9) (size at which the cumulative volume reaches 90% of the total volume), of micro-encapsulates with diameters in the range of 0.2-2000 pm.
  • RTM laser diffractometery
  • Measurement of microencapsulate size is performed at 25°C and six runs are performed for each replicate batch (Doherty et al., 201 11 ) (Development and characterisation of whey protein micro-beads as potential matrices for probiotic protection, S.B. Doherty, V.L. Gee, R.P. Ross, C. Stanton, G.F.
  • the microencapsulate is substantially spherical as shown in the attached figures.
  • the microparticle comprises microemulsified hemp derivative or hemp oil dispersed throughout a polymerised protein matrix.
  • the hemp derivative may be powdered hemp plant matter.
  • “Microemulsified hemp oil” means droplets of hemp oil dispersed through the protein matrix of the microparticle.
  • the droplets comprise a suitable surfactant, for example a
  • the droplets typically have an average dimension as measured by electron microscopy of less than 20 or 10 microns, and ideally about 5 microns.
  • the small droplet size is achieved by forming the microemulsion using high shear homogenisation.
  • Hemp derivative generally means a derivative product formed from any part of the hemp plant.
  • the hemp derivative is selected from hemp oil, powdered hemp plant matter, resinous hemp extract, cannabinoid fractions or hemp flour.
  • the hemp derivative may be any part selected from the hemp plant, for example special cuttings, flowers or flower parts, leaves or leaf parts, tops of plant whole plants or other parts or size selections, extracts or such part or isolated parts or fractions such as pure CBD,
  • “hemp fraction” or“hemp derivative” consists of powdered hemp leaves and or powdered hemp flowers.
  • Hemp powder should be understood to mean any“hemp derivative” or“hemp fraction” of the hemp plant, including seeds, typically the above-the-ground parts of the hemp plant, in a powder form.
  • the hemp powder is micronized hemp powder, for example micronized hemp flowers and leaves.
  • the hemp powder is micronized hemp stems and or stalks)
  • Cannabinoid rich as applied to a microparticle means a microparticle containing at least 30 mg cannabidiol (CBD) per gram of dried microparticles having a water activity (Aw) of 0.20. In one embodiment, the microparticle contains at least 35 mg, 40 mg, 45 mg, or 50 mg CBD per gram of dried microparticles having a water activity (Aw) of 0.20.
  • CBD cannabidiol
  • Gelated microparticle means a microparticle that is initially formed/extruded as a liquid microdroplet which is immediately cured in a polymerisation bath to form the gelated microparticle.
  • Suitable for delivery intact to the human lower intestine via an oral route means that the microparticle when delivered orally is capable of surviving gastric transit and being delivered to the lower intestine substantially intact.
  • Ileal-sensitive means that the microencapsulates are capable of releasing their contents in vivo in the ileum of a human.
  • the microparticles of the invention comprise a monodispersed matrix.
  • “Monodispersed matrix” means that the components of the microparticle are homogenously mixed in a single phase. This is distinct from microcapsules having a core-shell
  • “Gastro-resistant” means that the microencapsulates can survive intact for at least 60 minutes in the simulated stomach digestion model described in Minekus et al., 1999 and 2014 (A computer-controlled system to simulate conditions of the large intestine with peristaltic mixing, water absorption and absorption of fermentation product, Minekus, M., Smeets-Peeters M, Bernalier A, Marol-Bonnin S, Havenaar R, Marteau P, Alric M, Fonty G, Huis in't Veld JH, Applied Microbiology Biotechnology.
  • Protein means any protein susceptible to thermal or enzymatic denaturation, for example dairy protein or vegetable protein, or a mixture of dairy protein or vegetable protein.
  • the protein is a globular protein.
  • Denatured means partially or fully denatured. Preferably at least 90%, 95% or 99% of the protein is denatured. A method of determining the % of denatured protein is provided below.
  • the supernatant was diluted and the native protein concentration was determined using reverse phase HPLC using a Source and 5RPC column (Amersham Biosciences UK limited).
  • the HPLC system consisted of a Waters 2695 separation module with a Waters 2487 dual wavelength absorbance detector. The data were acquired and processed using Waters empower software (Milford, MA, USA).
  • Hydrolysis means any protein that has been hydrolysed to at least partially break up the protein into smaller peptide or polypeptides. It can be fully or partially hydrolysed. The degree of hydrolysis (%DH) may be variable and can be determined by routine
  • the protein is hydrolysed to a degree of from 10% to 99%, typically, from 15% to 95%, typically from 20% to 65%, suitably 45%.
  • Degree of hydrolysis is defined as the proportion of cleaved peptide bonds in a protein hydrolysate, and may be determined using the OPA spectrophotometric assay, which involve the using N- acetyl-L-Cysteine (NAC) as the thiol reagent.
  • NAC N- acetyl-L-Cysteine
  • One means to determine %DH is using a method of hydrolysis of proteins performed at high temperatures and for short times with reduced racemization in order to determine the enantiomers of D and L amino acids, Csapo, J. et al., Acta Univ, Sapientiae, Alimentaria, 2008; pg 31-48.
  • Methods of hydrolysis are known to a person skilled in the art and include thermal and proteolytic hydrolysis.
  • Dairy protein means any protein source isolated from expressed from the mammary glands of a female mammal.
  • Dairy proteins include Milk protein concentrate or isolates (MPC or MPI) - Milk protein concentrates are produced by ultrafiltration (UF) of milk - or whey protein concentrates or isolates or caseinates.
  • the product in liquid form is generally referred to as UF milk while the dry form is known as MPC.
  • MPC milk protein concentrate
  • This product contains unaltered forms of both casein and whey protein.
  • the level of protein, lactose and mineral present vary depending on the degree of protein concentration.
  • Pea protein should be understood to mean protein obtained from pea, typically total pea protein.
  • the pea protein is pea protein isolate (PPI), pea protein concentrate (PPC), or a combination of either.
  • the liquid core comprises 6-8% pea protein, ideally 6.6-7.5% (w/v).
  • the solvent for the pea protein has a pH of greater than 10 or 10.5.
  • the pea protein is solubilised in an alkali solvent.
  • Hemp oil refers to an oil or extract fraction derived from any part of the hemp plant of the Cannabis Sativa L. family. It generally contains less than 0.2% tetrahydrocannabinol (THC) (w/w) and 2 - 96 % of cannabidiol (CBD).
  • THC tetrahydrocannabinol
  • CBD cannabidiol
  • the hemp oil employed in the process and products of the present invention may be obtained from hemp seeds, or from hemp plant matter, or both.
  • the process of the invention provides hemp oil in a microemulsion form in a gelated protein matrix, in which the cannabinoid content content of the oil is high, for example more than 40 or 50 mg/ g microparticles.
  • Crobidiol or“CBD” refers to a specific cannabinoid present in hemp oil. It is described in Mechoulam et al (Journal of Clinical Pharmacology, (2002) 42 (1 1 Suppl)). Rustichelli et al 1998 describes how direct gas chromatography (GC) analysis can only determine the total cannabinoid content of plant tissue extracts. This is due to the acidic cannabinoid compounds being converted to neutral cannabinoids by high temperatures when injected into a GC system. High performance liquid chromatography (HPLC) can detect both the acidic and neutral forms of cannabinoids.
  • GC gas chromatography
  • This paper outlines a room temperature method of analysis with a mobile phase of methanol/ water in the ration of 80:20 (v/v).
  • the flow rate was set to 1.0ml/L min 1 and the injection volume was 20.0mI_.
  • a mass spectrophotometer (MS) was also used as a method of detection.
  • the mass range of m/z 45-700 was scanned once per second.
  • the following parameters were set on the MS; the electron impact (El) mode was enabled, ionization energy 70eV; ion source temperature 250°C, filament current 200mA, conversion dynode power -15kV and electron multiplier voltage 1500V.
  • CBD CBD-A
  • THC Tetrahydrocannabinol
  • CBCh Cannabichromene
  • HPLC-MS HPLC-MS.
  • a HPLC -UV with an ultra violet detector array set at 220nm with 0.04 absorbance full scale is commonly used to measure cannabinoid content.
  • HPLC /DAD method can also be used (References: De Backer, B., Debrus, B., Lebrun, P., Thenunis, L., Dubois, N., Decock, L., Verstraete, A., Hubert, P. and Charlier, C. (2009) innovative development and validation of an HPLC/DAD method for the qualitative and quantitative determination of major cannabinoids in cannabis plant material. Journal of Chromatography B, 877(2009) 4115-4124 / Rustichelli, C., Ferioli, V., Baraldi, M., Zanoli, P. and Gamberini, G. (1998) Analysis of Cannabinoids in Fiber Hemp Plant Varieties (Cannabis Sativa L.) by High-Performance Liquid Chromatography. Chromatographia Vol. 47, No. 3 ⁇ 4).
  • “Microemulsion” means a hemp oil emulsion that is formed between hemp oil, an aqueous protein phase and a surfactant by homogenisation under high shear conditions, typically using an Ultraturrax homogeniser with a hemp oil droplet size of less than 20 microns and preferably less than 10 microns.
  • “Non-ionic surfactant” refers to a surfactant having covalently bonded oxygen-containing hydrophilic groups, which are bonded to hydrophobic parent structures. Examples include Triton X-100, and fatty acid esters of glycerol or sorbitol.
  • Polysorbate-type non-ionic surfactant refers to a class of non-ionic surfactants derived from ethoxylated sorbitan esterified with fatty acids. Common brand names for
  • polysorbates include TWEEN (RTM), SCATTICS (RTM), ALKEST (RTM) and CANCAREL (RTM).
  • the Polysorbate-type non-ionic surfactant is a TWEEN (RTM), for example one of TWEEN (RTM) 20, TWEEN (RTM) 40, TWEEN (RTM) 60 or TWEEN (RTM) 80.
  • Polymerisation bath means a bath of liquid configured to polymerise the microdroplets of microemulsion.
  • the polymerisation is acidification bath comprising an acidic buffer, for example an acetate salt buffer.
  • the acidification bath has a pH of less than 5, for example 3.5 to 4.7, 3.8 to 4.6, or 3.8 to 4.4.
  • the acidification bath typically has a buffer concentration of 0.1 M to 0.8M, preferably 0.3M to 0.7M, and more preferably 0.4M to 0.6M.
  • the acidification bath comprises surfactant.
  • the acidification bath comprises 0.01 to 1.1% surfactant or co-surfactant or both.
  • the surfactant is a hydrophilic surfactant.
  • the surfactant is a TWEEN (RTM) (TWEEN (RTM) -20 or TWEEN (RTM)-80) surfactant.
  • Particle Size means the size of a spherical particle expressed as the diameter measurement. For non-spherical particles, the size can be represented as an apparent diameter.
  • Size distribution relates to the fact that droplets and particles that are produced in a spray dryer are never of one particular size. Any nozzle will produce both large and small droplets. The dryer must operate so that it is able to dry the largest droplet without scorching the smallest one. Size distributions can be represented by a cumulative distribution curve. Particle size distributions were measured with a Nicomp model 380 ZLS particle size system (Nicomp PSS, Santa Barbara, CA, USA). Measurements were taken at 23 °C using a 635 nm source and a scattering angle of 90°. Samples were prepared for measurement by dilution in deionized water.
  • Calorimetry data were collected with a TA Instruments model Q20 differential scanning calorimeter (TA Instruments, New Castle, DE, USA). The instrument was calibrated with an Indium standard. Aluminium sample pans were used and samples were scanned at 5 °C/min over the temperature range of 25 °C to 90 °C.
  • Water activity (Aw) The water activity (Aw) of a food / ingredient is the ratio between the vapour pressure of the ingredient itself, when in a completely undisturbed balance with the surrounding air media, and the vapour pressure of distilled water under identical conditions.
  • the most common method used to measure water activity is the Equilibrium Relative Humidity equation (ERH), which is expressed in percentage or as the water activity expressed as a decimal.
  • EH Equilibrium Relative Humidity equation
  • a portion of the total water content present in food is strongly bound to specific sites and does not act as a solvent. These sites include the hydroxyl groups of polysaccharides, the carbonyl and amino groups of proteins, and others on which water can be held by hydrogen bonding, by ion-dipole bonds, or by other strong
  • ERH is the equilibrium relative humidity (%).
  • Relative humidity sensors of great variety are available for this purpose, including electric hygrometers, dewpoint cells, psychrometers, and others.
  • Water dispersible as applied to the gelated microparticles of the invention means that microparticulates do not sediment in an aqueous solution and sedimentation measured no more than 1 % of the hydrated material content. Gelated microparticles will remained in a suspended state in an aqueous solution.
  • “Stable to oxidation” as applied to the microemulsified hemp oil in the gelated microparticles means that the hemp oil is stable as per measurements for primary and secondary oxidation. This testing is conducted using Peroxide value (AOCS Cd 8b-90) and Anisidine value (AOCS Cd 18-90) testing. Acceptable ranges for primary (PoV) and secondary (AnV) oxidation would be 3-9 meq and 15-17 units, respectively. Values above these ranges would be consider oxidsed and unstable.
  • TWEEN (RTM) 20 was mixed with 1 1 % milk protein isolate until the TWEEN (RTM) 20 was completely dissolved (Table 1 ). Oil was added dropwise to homogenise the suspension.
  • the suspension was placed on the micro-encapsulator and set up. Some oil was visible on the surface of emulsion. Micro-encapsulation the settings were adjusted to improve bead chain.
  • the encapsulation dish was removed from the stir plate and the 0.5M sodium acetate waste was poured off the beads. The beads were rinsed in water before and sieved.
  • the wet beads were further dried for 2- 4 hours, with the option of using a drying aid, depending on the origin of the oil extract/ distillate ( Figure 2).
  • Polysorbate 80 was mixed with 15% PPI (pea protein isolate) until the dispersion was completely dissolved. Oil was added dropwise to homogenise the suspension.
  • the suspension was micro-encapsulated and polymerised using sodium acetate. Micro- encapsulation the settings were adjusted to improve bead chain.
  • the encapsulation dish was removed from the stir plate and sodium acetate waste was poured off the beads. The beads were rinsed in water before and sieved.
  • the wet beads were further dried for 2- 4 hours, with the option of using a drying aid, depending on the origin of the oil extract/ distillate.
  • EE (Encapsulation efficiency) is defined as the amount of CBD loaded into the
  • the Encapsulation Efficiency is calculated as follows by determining the free CBD concentration, and the total amount of CBD (Initial CBD concentration, raw material).
  • CBD concentration the encapsulated samples were dissolved in MilliQ H20. Raw samples were managed in similar technique and dilutions were accounted to equilibrate the systems.
  • the aqueous solution is diluted x2 in methanol and sonicated for 3 minutes. Aliquots (200 pi) were further diluted with methanol to x50 volume.
  • Figure 18B shows the superior improvement in CBD permeation in the body as a result of invention presented.
  • Figure 18 demonstrates that the micro-encapsulated Cannabinoid-Rich Hemp Oil has a greater permeation capacity relative to free Hemp Oil.
  • Digestion of 5 mg dose of micro- encapsulated Hemp Oil illustrated a greatest reduction in % TEER compared to micro- encapsulated Hemp Oil 10 mg doses of micro-encapsulated Hemp Oil.
  • reduction in %TEER is dependent on the i) presence of micro-encapsulated Hemp Oil and ii) concentration of micro-encapsulated cannabinoids.
  • Figure 18 shows that free Hemp Oil have an expected permeability across the gut epithelial tissue; however, micro-encapsulated Hemp Oil provides a greater permeability and bioavailability of its cannabinoids measured by CBD via the use of micro-encapsulation technology and the use of a lower doses (5 mg) concentration of micro-encapsulated Cannabinoid-Rich Hemp Oil. It is important to note that the permeability after 120 min is approx similar between the two doses (5 mg vs. 10 mg CBD) of micro-encapsulated Cannabinoid-Rich Hemp Oil, which both show an above 80 % bioavailability, which is significantly higher than inhalation by smoking which only show approx.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une microparticule gélifiée riche en cannabinoïdes qui comprend de l'huile de chanvre microémulsifiée dispersée dans l'ensemble d'une matrice de protéine polymérisée, dans laquelle la microparticule est gastro-résistante et sensible à l'iléal, et dans laquelle l'huile de chanvre microémulsifiée est stable à l'oxydation. Le tensioactif dans l'huile de chanvre microémulsifiée comprend un tensioactif non ionique de type polysorbate. La protéine peut être choisie parmi une protéine laitière ou une protéine végétale.
PCT/EP2019/062395 2018-05-14 2019-05-14 Microparticules de protéines gélifiées riches en cannabinoïdes WO2019219713A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19728883.0A EP3793528A1 (fr) 2018-05-14 2019-05-14 Microparticules de protéines gélifiées riches en cannabinoïdes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1807801.4 2018-05-14
GBGB1807801.4A GB201807801D0 (en) 2018-05-14 2018-05-14 Microparticles

Publications (2)

Publication Number Publication Date
WO2019219713A1 true WO2019219713A1 (fr) 2019-11-21
WO2019219713A9 WO2019219713A9 (fr) 2020-01-23

Family

ID=62623345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/062395 WO2019219713A1 (fr) 2018-05-14 2019-05-14 Microparticules de protéines gélifiées riches en cannabinoïdes

Country Status (3)

Country Link
EP (1) EP3793528A1 (fr)
GB (1) GB201807801D0 (fr)
WO (1) WO2019219713A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022200636A1 (fr) * 2021-03-26 2022-09-29 Insucaps Limited Formulations pharmaceutiques et leurs procédés de production
WO2023144352A1 (fr) * 2022-01-27 2023-08-03 Insucaps Limited Nano-émulsions huile-dans-eau et leurs procédés de production et d'utilisation
WO2024001738A1 (fr) * 2022-06-30 2024-01-04 东北农业大学 Microcapsule de cannabidiol soluble dans l'eau et sa méthode de préparation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
EP0856355A2 (fr) 1997-01-31 1998-08-05 Givaudan-Roure (International) S.A. Particules à base d'huile encapsulées par une protéine
WO2002064109A2 (fr) 2001-02-14 2002-08-22 Gw Pharma Limited Preparations pharmaceutiques
WO2002092217A1 (fr) 2001-05-16 2002-11-21 Mainelab Microcapsules a base de proteines vegetales
WO2012038061A2 (fr) 2010-09-21 2012-03-29 Lipotec, S.A. Nanocapsules contenant des microémulsions
WO2017137992A1 (fr) * 2016-02-11 2017-08-17 Gelpell Ag Formulations orales solides de cannabinoïdes, leurs procédés de production et d'utilisation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
EP0856355A2 (fr) 1997-01-31 1998-08-05 Givaudan-Roure (International) S.A. Particules à base d'huile encapsulées par une protéine
WO2002064109A2 (fr) 2001-02-14 2002-08-22 Gw Pharma Limited Preparations pharmaceutiques
WO2002092217A1 (fr) 2001-05-16 2002-11-21 Mainelab Microcapsules a base de proteines vegetales
WO2012038061A2 (fr) 2010-09-21 2012-03-29 Lipotec, S.A. Nanocapsules contenant des microémulsions
WO2017137992A1 (fr) * 2016-02-11 2017-08-17 Gelpell Ag Formulations orales solides de cannabinoïdes, leurs procédés de production et d'utilisation

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CSAPO, J. ET AL., ACTA UNIV, SAPIENTIAE, ALIMENTARIA, 2008, pages 31 - 48
DE BACKER, B.DEBRUS, B.LEBRUN, P.THENUNIS, L.DUBOIS, N.DECOCK, L.VERSTRAETE, A.HUBERT, P.CHARLIER, C.: "Innovative development and validation of an HPLC/DAD method for the qualitative and quantitative determination of major cannabinoids in cannabis plant material", JOURNAL OF CHROMATOGRAPHY B, vol. 877, 2009, pages 4115 - 4124, XP026791284
JU, Z. Y.KILARA, A.: "Gelation of Ph-Aggregated Whey Protein Isolate Solution Induced by Heat, Calcium Salt and Acidulant", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 46, no. 5, 1998, pages 1830 - 1835, XP002146903, DOI: doi:10.1021/jf9710185
MECHOULAM ET AL., JOURNAL OF CLINICAL PHARMACOLOGY, vol. 42, no. 11, 2002
MINEKUS, A. ET AL., FOOD FUNCTION, vol. 5, 2014, pages 1113
MINEKUS, M.SMEETS-PEETERS MBERNALIER AMAROL-BONNIN SHAVENAAR RMARTEAU PALRIC MFONTY GHUIS IN'T VELD JH, APPLIED MICROBIOLOGY BIOTECHNOLOGY, vol. 53, no. 1, December 1999 (1999-12-01), pages 108 - 14
OHLSSON A ET AL., BIOMED ENVIRON MASS SPECTROM, vol. 13, no. 2, February 1986 (1986-02-01), pages 77 - 83
RUSTICHELLI, C.FERIOLI, V.BARALDI, M.ZANOLI, P.GAMBERINI, G.: "Analysis of Cannabinoids in Fiber Hemp Plant Varieties (Cannabis Sativa L.) by High-Performance Liquid Chromatography", CHROMATOGRAPHIA, vol. 47, no. ¾, 1998
S.B. DOHERTYV.L. GEER.P. ROSSC. STANTONG.F. FITZGERALDA. BRODKORB, FOOD HYDROCOLLOIDS, vol. 25, no. 6, August 2011 (2011-08-01), pages 1604 - 1617

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022200636A1 (fr) * 2021-03-26 2022-09-29 Insucaps Limited Formulations pharmaceutiques et leurs procédés de production
WO2023144352A1 (fr) * 2022-01-27 2023-08-03 Insucaps Limited Nano-émulsions huile-dans-eau et leurs procédés de production et d'utilisation
WO2024001738A1 (fr) * 2022-06-30 2024-01-04 东北农业大学 Microcapsule de cannabidiol soluble dans l'eau et sa méthode de préparation

Also Published As

Publication number Publication date
WO2019219713A9 (fr) 2020-01-23
EP3793528A1 (fr) 2021-03-24
GB201807801D0 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
Belščak-Cvitanović et al. Emulsion templated microencapsulation of dandelion (Taraxacum officinale L.) polyphenols and β-carotene by ionotropic gelation of alginate and pectin
Sari et al. Preparation and characterization of nanoemulsion encapsulating curcumin
Liu et al. Encapsulation of curcumin in zein/caseinate/sodium alginate nanoparticles with improved physicochemical and controlled release properties
Binsi et al. Structural and oxidative stabilization of spray dried fish oil microencapsulates with gum arabic and sage polyphenols: Characterization and release kinetics
Colín-Cruz et al. Co-encapsulation of bioactive compounds from blackberry juice and probiotic bacteria in biopolymeric matrices
Jannasari et al. Microencapsulation of vitamin D using gelatin and cress seed mucilage: Production, characterization and in vivo study
Castel et al. Brea gum as wall material in the microencapsulation of corn oil by spray drying: Effect of inulin addition
WO2019219713A1 (fr) Microparticules de protéines gélifiées riches en cannabinoïdes
Wang et al. Nano-encapsulations liberated from barley protein microparticles for oral delivery of bioactive compounds
US7867545B2 (en) Homogenous granular solid matrix containing vegetable protein
Thakur et al. Microencapsulation of β-carotene based on casein/guar gum blend using zeta potential-yield stress phenomenon: An approach to enhance photo-stability and retention of functionality
Khanji et al. Structure, gelation, and antioxidant properties of curcumin-doped casein micelle powder produced by spray-drying
Li et al. Microencapsulation of vitamins, minerals, and nutraceuticals for food applications
RU2164406C2 (ru) Способ инкапсулирования материала ядра
Bodade et al. Microencapsulation of bioactive compounds and enzymes for therapeutic applications
Farrag et al. Research Article Microencapsulation of Grape Phenolic Compounds Using Whey Proteins as a Carrier Vehicle
Molaveisi et al. Vitamin D3‐loaded nanophytosomes for enrichment purposes: Formulation, structure optimization, and controlled release
Comunian et al. Influence of heated, unheated whey protein isolate and its combination with modified starch on improvement of encapsulated pomegranate seed oil oxidative stability
Paulo et al. Propolis microencapsulation by double emulsion solvent evaporation approach: Comparison of different polymeric matrices and extract to polymer ratio
DK2197493T3 (en) MICROENCAPSULATED LIPOSOMAL COMPOSITIONS
Dadwal et al. Development and characterization of controlled released polyphenol rich micro‐encapsulate of Murraya koenigii bark extract
CN108882729A (zh) 脂溶性活性成分的纳米胶囊，其制造和用途
US20220378699A1 (en) Self-emulsifying cannabis extract
Nikolić et al. Potential of encapsulated phytochemicals in hydrogel particles
Wilar et al. Microparticles of herbal extracts with antioxidant activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19728883

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019728883

Country of ref document: EP

Effective date: 20201214